JP2004503581A - 医薬エアゾール製剤 - Google Patents

医薬エアゾール製剤 Download PDF

Info

Publication number
JP2004503581A
JP2004503581A JP2002511717A JP2002511717A JP2004503581A JP 2004503581 A JP2004503581 A JP 2004503581A JP 2002511717 A JP2002511717 A JP 2002511717A JP 2002511717 A JP2002511717 A JP 2002511717A JP 2004503581 A JP2004503581 A JP 2004503581A
Authority
JP
Japan
Prior art keywords
formulation
amino
group
drug
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002511717A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004503581A5 (OSRAM
Inventor
アドジェイ，アクウィート　エル
キューティー，アンソニー　ジェイ
Original Assignee
エアロファーム　テクノロジー　インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エアロファーム　テクノロジー　インコーポレイテッド filed Critical エアロファーム　テクノロジー　インコーポレイテッド
Publication of JP2004503581A publication Critical patent/JP2004503581A/ja
Publication of JP2004503581A5 publication Critical patent/JP2004503581A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2002511717A 2000-07-17 2000-12-07 医薬エアゾール製剤 Pending JP2004503581A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/617,328 US6458338B1 (en) 1998-09-22 2000-07-17 Amino acid stabilized medicinal aerosol formulations
PCT/US2000/042624 WO2002005784A1 (en) 2000-07-17 2000-12-07 A medicinal aerosol formulation

Publications (2)

Publication Number Publication Date
JP2004503581A true JP2004503581A (ja) 2004-02-05
JP2004503581A5 JP2004503581A5 (OSRAM) 2005-11-17

Family

ID=24473199

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002511717A Pending JP2004503581A (ja) 2000-07-17 2000-12-07 医薬エアゾール製剤

Country Status (7)

Country Link
US (1) US6458338B1 (OSRAM)
EP (1) EP1301173A1 (OSRAM)
JP (1) JP2004503581A (OSRAM)
AU (2) AU2001245190B2 (OSRAM)
CA (1) CA2416403C (OSRAM)
MX (1) MXPA03000442A (OSRAM)
WO (1) WO2002005784A1 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020528453A (ja) * 2017-07-20 2020-09-24 エーゼットセラピーズ， インコーポレイテッド クロモリンナトリウムおよびイブプロフェンの粉末製剤
KR20230039906A (ko) * 2021-09-15 2023-03-22 구주제약주식회사 안정성이 향상된 프로피오닉산 계열 약물 및 안정화제를 포함하는 약학 조성물

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7014870B1 (en) * 1992-11-06 2006-03-21 Greystone Medical Group, Inc. Compositions of oak bark extract related synthetic compositions and method of using same
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US20040037898A1 (en) * 1997-10-08 2004-02-26 Hon David N.S Compositions of oak bark extract, related synthetic compositions and method of using same
US7074388B2 (en) * 1998-12-10 2006-07-11 Kos Life Science, Inc. Water stabilized medicinal aerosol formulation
US20020076382A1 (en) * 2000-08-04 2002-06-20 Kaplan Leonard W. Formulations of mometasone and a bronchodilator for pulmonary administration
US6858596B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6787532B2 (en) * 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
CA2518102C (en) * 2003-03-04 2009-05-12 Tanabe Seiyaku Co., Ltd. Powdery preparation for nasal administration
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
US20060020035A1 (en) * 2004-03-11 2006-01-26 Oregon Health & Science University Bone marrow protection with N-acetyl-L-cysteine
US8367734B1 (en) 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency
EP1968546A2 (en) * 2005-12-21 2008-09-17 Nitrox, LLC Stables s-nitrosothiol formulations
US20080063722A1 (en) * 2006-09-08 2008-03-13 Advanced Inhalation Research, Inc. Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI)
US7951368B2 (en) * 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
TWI399202B (zh) 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
GB201113662D0 (en) * 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
JP2015512929A (ja) * 2012-04-11 2015-04-30 シプラ・リミテッド 医薬組成物
SI2931713T1 (sl) 2012-12-17 2017-03-31 Parion Sciences, Inc. Derivati kloro-pirazin karboksamida uporabni za zdravljenje bolezni favoriziranih z nezadostno hidracijo sluznice
EP2931712B8 (en) 2012-12-17 2018-05-23 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
WO2015120453A1 (en) * 2014-02-10 2015-08-13 University Of South Florida Hormone treatment for age-related hearing loss-presbycusis
CN106138014A (zh) * 2015-03-25 2016-11-23 天津金耀集团有限公司 一种含有糖皮质激素的气雾剂药物组合物
CN106137964A (zh) * 2015-03-25 2016-11-23 天津金耀集团有限公司 一种含有丙酸倍氯米松的气雾剂药物组合物
CN106137965A (zh) * 2015-03-25 2016-11-23 天津金耀集团有限公司 一种含有环索奈德的气雾剂药物组合物
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
BR112020002419A2 (pt) 2017-08-14 2020-07-28 Axcella Health Inc. aminoácido para o tratamento de doença do fígado
CN110302157B (zh) * 2018-03-27 2023-01-17 天津金耀集团有限公司 一种异丙托溴铵气雾剂组合物及其制备方法
CN112839643A (zh) 2018-06-20 2021-05-25 胺细拉健康公司 用于治疗肌肉中脂肪浸润的组合物及方法
CN110755414A (zh) * 2019-11-12 2020-02-07 南京华盖制药有限公司 一种酒石酸阿福特罗气雾剂及其制备方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (OSRAM) 1956-03-21 1900-01-01
US2885427A (en) 1956-11-15 1959-05-05 Dow Chemical Co Fluorination of trichloroethylene
US3261748A (en) 1964-07-17 1966-07-19 Dow Chemical Co 1,1,1,2-tetrafluoroethane anesthetic
NL7708731A (nl) 1976-08-13 1978-02-15 Montedison Spa Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen.
US4129603A (en) 1978-02-07 1978-12-12 Imperial Chemical Industries Limited Manufacture of halogenated compounds
CA1136547A (en) 1979-03-08 1982-11-30 Song-Ling Lin Aerosol anesthetic compositions
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
EP0460064A4 (en) 1989-02-23 1992-04-01 Rorer International (Holdings) Inc. Therapeutic aerosol formulations
US5439670A (en) 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
US5376386A (en) 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
DE4003272A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
US5126123A (en) 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
US5182097A (en) 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US5190029A (en) 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
EP1092430B1 (en) 1991-06-10 2003-08-06 Schering Corporation Non-chlorofluorocarbon aerosol formulations
EP0587790B2 (en) 1991-06-10 2000-03-08 Schering Corporation Non-chlorofluorocarbon aerosol formulations
JPH04366411A (ja) 1991-06-13 1992-12-18 Ngk Insulators Ltd 薄膜磁気ヘッド
ATE128350T1 (de) 1991-12-12 1995-10-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung.
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5658549A (en) 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5736124A (en) 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5683676A (en) 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US5744123A (en) 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5674471A (en) 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
GB9202519D0 (en) 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
US5607662A (en) 1992-03-10 1997-03-04 Fisons, Plc Pharmaceutical inhalation compositions
WO1994021229A1 (en) 1993-03-17 1994-09-29 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
US5492688A (en) 1993-04-28 1996-02-20 The Center For Innovative Technology Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
EP0731688B1 (en) * 1993-12-02 2003-03-05 Abbott Laboratories Aerosol drug formulations for use with non-cfc propellants
DK0735884T3 (da) 1993-12-20 2000-10-09 Minnesota Mining & Mfg Flunisolid-aerosolformuleringer
US5594015A (en) 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
US5635159A (en) * 1994-08-26 1997-06-03 Abbott Laboratories Aerosol drug formulations containing polyglycolyzed glycerides
GB9425160D0 (en) * 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
SK81197A3 (en) * 1994-12-22 1997-11-05 Astra Ab Aerosol drug formulations, method for production thereof and its use
US5612053A (en) 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5603918A (en) * 1995-06-09 1997-02-18 Boehringer Ingelheim Pharmaceuticals, Inc. Aerosol composition of a salt of ipratropium and a salt of albuterol
US6193954B1 (en) 1997-03-21 2001-02-27 Abbott Laboratories Formulations for pulmonary delivery of dopamine agonists
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US5891420A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020528453A (ja) * 2017-07-20 2020-09-24 エーゼットセラピーズ， インコーポレイテッド クロモリンナトリウムおよびイブプロフェンの粉末製剤
JP7202376B2 (ja) 2017-07-20 2023-01-11 エーゼットセラピーズ， インコーポレイテッド クロモリンナトリウムおよびイブプロフェンの粉末製剤
KR20230039906A (ko) * 2021-09-15 2023-03-22 구주제약주식회사 안정성이 향상된 프로피오닉산 계열 약물 및 안정화제를 포함하는 약학 조성물
KR102675664B1 (ko) * 2021-09-15 2024-06-17 구주제약주식회사 안정성이 향상된 프로피오닉산 계열 약물 및 안정화제를 포함하는 약학 조성물

Also Published As

Publication number Publication date
WO2002005784A1 (en) 2002-01-24
CA2416403A1 (en) 2002-01-24
EP1301173A1 (en) 2003-04-16
MXPA03000442A (es) 2003-06-24
US6458338B1 (en) 2002-10-01
AU2001245190B2 (en) 2005-04-07
CA2416403C (en) 2009-01-27
AU4519001A (en) 2002-01-30

Similar Documents

Publication Publication Date Title
JP2004503581A (ja) 医薬エアゾール製剤
CN100337614C (zh) 医用气溶胶制剂
AU2001245190A1 (en) A medicinal aerosol formulation
US7074388B2 (en) Water stabilized medicinal aerosol formulation
US6261539B1 (en) Medicinal aerosol formulation
JP2003520829A (ja) 医薬エアゾール製剤
US20240091148A1 (en) Eutectic solvents comprising pharmaceutical agents, and methods of making and use thereof
WO2002007672A2 (en) A medicinal aerosol formulation
AU2021314977B2 (en) Combination therapy for inhalation administration
AU2007231727B2 (en) Water stabilized medicinal aerosol formulation
HK1097777B (en) Medicinal aerosol formulation
WO2002015883A1 (en) A method of stabilizing a dry powder pharmaceutical formulation
HK1041835B (en) Medicinal aerosol formulation
HK1042858A (en) A medicinal aerosol formulation
MXPA01005716A (en) A medicinal aerosol formulation

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20040106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040506

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040506

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080701

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080708

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081224